The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.

Bristol-Myers Squibb (NYSE:BMY) is acquiring Orbital Therapeutics in a $1.5b deal to expand its next generation RNA therapy ...

Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.

Chris Boerner, Bristol Myers Squibb CEO, joins 'Power Lunch' to discuss the company's quarterly earnings results, the drug ...

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.

Bristol Myers Squibb Company (NYSE:BMY) is one of the most undervalued large cap stocks to invest in now. On January 28, ...

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies ...

Bristol Myers BMY recently collaborated with Bain Capital to create a new independent biopharmaceutical company, which will be focused on developing new therapies for autoimmune diseases that address ...